Description

The Overdrive features Retatrutide, an advanced triple-receptor agonist researched for its simultaneous engagement of GLP-1, GIP, and glucagon receptors — representing the next generation of metabolic peptide research compounds. Retatrutide’s unique tri-agonist mechanism makes it one of the most analytically complex and research-relevant metabolic peptides available, enabling investigations into multi-pathway energy regulation, adipose tissue mobilization, and comprehensive metabolic homeostasis. Research into Retatrutide explores its potential for superior weight reduction modeling, thermogenic signaling, glycemic regulation, and appetite suppression via simultaneous engagement of three distinct incretin and glucagon pathways. Available in 20mg, 30mg, and 60mg concentrations, The Overdrive provides scalable research options for preliminary studies through advanced, high-intensity metabolic investigations.